ES2460899T3 - Inmunoterapia basada en células cancerosas alógenas - Google Patents
Inmunoterapia basada en células cancerosas alógenas Download PDFInfo
- Publication number
- ES2460899T3 ES2460899T3 ES09720311.1T ES09720311T ES2460899T3 ES 2460899 T3 ES2460899 T3 ES 2460899T3 ES 09720311 T ES09720311 T ES 09720311T ES 2460899 T3 ES2460899 T3 ES 2460899T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- tumor
- subject
- mice
- lymphocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 148
- 201000011510 cancer Diseases 0.000 title claims abstract description 58
- 238000009169 immunotherapy Methods 0.000 title description 11
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 17
- 239000013598 vector Substances 0.000 claims description 17
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 124
- 241000699670 Mus sp. Species 0.000 description 49
- 210000003719 b-lymphocyte Anatomy 0.000 description 43
- 230000003053 immunization Effects 0.000 description 41
- 238000002649 immunization Methods 0.000 description 41
- 238000002255 vaccination Methods 0.000 description 34
- 239000000427 antigen Substances 0.000 description 32
- 108091007433 antigens Proteins 0.000 description 32
- 102000036639 antigens Human genes 0.000 description 32
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 16
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 16
- 108010088751 Albumins Proteins 0.000 description 15
- 102000009027 Albumins Human genes 0.000 description 15
- 230000002163 immunogen Effects 0.000 description 15
- 229960005486 vaccine Drugs 0.000 description 15
- 108010058846 Ovalbumin Proteins 0.000 description 13
- 238000007912 intraperitoneal administration Methods 0.000 description 12
- 230000001404 mediated effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 230000001629 suppression Effects 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 230000006698 induction Effects 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 210000003200 peritoneal cavity Anatomy 0.000 description 9
- 230000007115 recruitment Effects 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 230000001506 immunosuppresive effect Effects 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 5
- 206010062016 Immunosuppression Diseases 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 5
- 230000005809 anti-tumor immunity Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 230000033289 adaptive immune response Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000003230 b-1 b lymphocyte Anatomy 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 230000006041 cell recruitment Effects 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 210000004479 myeloid suppressor cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010086377 HLA-A3 Antigen Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003039 myelosuppressive effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001176—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3342508P | 2008-03-03 | 2008-03-03 | |
| US33425P | 2008-03-03 | ||
| PCT/US2009/001330 WO2009114085A2 (en) | 2008-03-03 | 2009-03-03 | Allogeneic cancer cell-based immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2460899T3 true ES2460899T3 (es) | 2014-05-14 |
Family
ID=41065702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09720311.1T Active ES2460899T3 (es) | 2008-03-03 | 2009-03-03 | Inmunoterapia basada en células cancerosas alógenas |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8475785B2 (enExample) |
| EP (2) | EP2257301B1 (enExample) |
| JP (2) | JP2011513399A (enExample) |
| KR (1) | KR20110009095A (enExample) |
| CN (1) | CN102014937A (enExample) |
| AU (1) | AU2009223838B2 (enExample) |
| CA (1) | CA2717854C (enExample) |
| DK (1) | DK2257301T3 (enExample) |
| ES (1) | ES2460899T3 (enExample) |
| IL (1) | IL207958A (enExample) |
| WO (1) | WO2009114085A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2355483T3 (es) | 1998-02-20 | 2011-03-28 | University Of Miami | Complejo de proteina de choque térmico modificada-péptido antigénico. |
| EP2257301B1 (en) | 2008-03-03 | 2014-01-22 | The University of Miami | Allogeneic cancer cell-based immunotherapy |
| CA2718884C (en) | 2008-03-20 | 2016-11-22 | University Of Miami | Heat shock protein gp96 vaccination and methods of using same |
| CN102223894A (zh) * | 2008-11-21 | 2011-10-19 | 迈阿密大学 | 用于产生粘膜和系统免疫的hiv/siv疫苗 |
| AU2011255463A1 (en) * | 2010-05-21 | 2012-11-01 | University Of Miami | Cancer treatment |
| CN104136040B (zh) * | 2012-01-20 | 2021-05-25 | 费尔南多·托姆·克罗伊茨 | 自体癌细胞疫苗 |
| WO2015131176A1 (en) * | 2014-02-28 | 2015-09-03 | Podack Eckhard R | Compositions, methods, and kits for treatment of cancer |
| KR20170109582A (ko) | 2015-02-06 | 2017-09-29 | 히트 바이오로직스, 인코퍼레이티드 | 벡터 공동 발현 백신 및 공동 자극 분자 |
| CA3040123A1 (en) | 2016-10-11 | 2018-04-19 | University Of Miami | Vectors and vaccine cells for immunity against zika virus |
| CA3058938A1 (en) | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
| US20200308299A1 (en) * | 2017-04-28 | 2020-10-01 | National University Corporation Kochi University | Anti-gpc-1 antibody |
| DE102021124078A1 (de) | 2021-09-17 | 2023-03-23 | Timm Golüke | Kosmetikzusammensetzung zur Anwendung auf der Haut |
Family Cites Families (159)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US5217891A (en) | 1987-07-28 | 1993-06-08 | Chiron Corporation | DNA constructs containing a kluyveromyces α factor leader sequence for directing secretion of heterologous polypeptides |
| WO1989012455A1 (en) | 1988-06-15 | 1989-12-28 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
| US5137819A (en) | 1988-07-08 | 1992-08-11 | University Of British Columbia | Cellulose binding fusion proteins for immobilization and purification of polypeptides |
| WO1990002564A1 (en) | 1988-09-12 | 1990-03-22 | Codon | Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi |
| US5232833A (en) | 1988-09-14 | 1993-08-03 | Stressgen Biotechnologies Corporation | Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| CA2064092C (en) | 1989-07-28 | 1996-05-21 | Toru Miki | Efficient directional genetic cloning system |
| GB9007194D0 (en) | 1990-03-30 | 1990-05-30 | Wellcome Found | Live vaccines |
| US5348945A (en) | 1990-04-06 | 1994-09-20 | Wake Forest University | Method of treatment with hsp70 |
| US5188964A (en) | 1990-04-12 | 1993-02-23 | Board Of Regents, The University Of Texas System | Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination |
| GB9016315D0 (en) | 1990-07-25 | 1990-09-12 | Burnie James P | Medicaments |
| GB9024320D0 (en) | 1990-11-08 | 1990-12-19 | Univ London | Treatment of uveitis |
| ES2104731T3 (es) | 1990-11-08 | 1997-10-16 | Univ London | Micobacterium utilizado como adyuvante para antigenos. |
| GB2251186A (en) | 1990-12-04 | 1992-07-01 | Randall Neal Gatz | Polypeptide for use in treatment of autoimmune disease |
| AU643141B2 (en) | 1991-03-15 | 1993-11-04 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| GB9200949D0 (en) | 1992-01-17 | 1992-03-11 | Medical Res Council | Diagnostic peptides |
| FR2688227A1 (fr) | 1992-03-04 | 1993-09-10 | Inst Nat Sante Rech Med | Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques. |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| FI944102A0 (fi) | 1992-03-09 | 1994-09-07 | Ist Naz Stud Cura Dei Tumori | Kasvaimen kasvua estämään kykenevä proteiiniyhdiste |
| JPH07505719A (ja) | 1992-04-14 | 1995-06-22 | デューク・ユニバーシティー | ｐ５３及びＨＳＰ７０のコンプレックスを含む腫瘍の検出方法 |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| WO1994003599A1 (fr) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc |
| GB2270076A (en) | 1992-08-18 | 1994-03-02 | Univ Manchester | Human HSP 90 Epitopes |
| GB9223816D0 (en) | 1992-11-13 | 1993-01-06 | Medical Res Council | Heat shock proteins and the treatment of tumours |
| NZ263550A (en) | 1993-03-19 | 1996-12-20 | Boehringer Ingelheim Int | Preparing cancer vaccines containing autologous tumour cells characterised in that tumour cells or firbroblasts are cultivated and transfected ex vivo with a composition of dna and a dna binding molecule conjugate |
| US5496934A (en) | 1993-04-14 | 1996-03-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acids encoding a cellulose binding domain |
| US5645829A (en) | 1993-06-18 | 1997-07-08 | Beth Israel Hospital Association | Mesothelial cell gene therapy |
| WO1995004824A1 (en) | 1993-08-05 | 1995-02-16 | Medvet Science Pty. Ltd. | Generation of dna libraries and retroviral vectors for same |
| US5705159A (en) | 1993-08-31 | 1998-01-06 | John Wayne Cancer Institute | Immunoreactive peptide sequence from a 43 KD human cancer antigen |
| US5444087A (en) | 1993-10-19 | 1995-08-22 | Bristol-Myers Squibb Company | Manumycin compounds |
| US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
| US5750119A (en) * | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
| CA2183667A1 (en) | 1994-02-22 | 1995-08-24 | Wayne A. Marasco | Nucleic acid delivery system, method of synthesis and uses thereof |
| US5961979A (en) | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| ES2125630T3 (es) | 1994-07-08 | 1999-03-01 | Baxter Int | Dispositivo implantable que contiene celulas tumorales, para el tratamiento del cancer. |
| US5772995A (en) | 1994-07-18 | 1998-06-30 | Sidney Kimmel Cancer Center | Compositions and methods for enhanced tumor cell immunity in vivo |
| CA2201587C (en) | 1994-10-03 | 2002-06-25 | Jeffrey Schlom | Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| US6719974B1 (en) | 1995-08-18 | 2004-04-13 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
| US6331299B1 (en) | 1995-08-18 | 2001-12-18 | Sloan-Kettering Institute For Cancer Research | Method for treatment of cancer and infectious disease and compositions useful in same |
| US6761892B1 (en) | 1995-08-18 | 2004-07-13 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
| CA2229543A1 (en) | 1995-08-18 | 1997-02-27 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
| US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
| US5985270A (en) | 1995-09-13 | 1999-11-16 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
| US5837251A (en) | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
| WO1997010000A1 (en) | 1995-09-13 | 1997-03-20 | Fordham University | Therapeutic and prophylactic methods using heat shock proteins |
| DE19602985A1 (de) | 1996-01-27 | 1997-07-31 | Max Delbrueck Centrum | Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren |
| WO1997026910A2 (de) | 1996-01-27 | 1997-07-31 | Max-Delbrück-Centrum für Molekulare Medizin | Tumorimpfstoff für die immuntherapie von malignen tumoren |
| BR9708387A (pt) | 1996-03-28 | 2000-01-04 | Genitrix Llc | Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada. |
| US5747332A (en) | 1996-09-20 | 1998-05-05 | University Of New Mexico | Methods for purifying and synthesizing heat shock protein complexes |
| US6130087A (en) | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
| AU736318B2 (en) | 1996-11-26 | 2001-07-26 | Nventa Biopharmaceuticals Corporation | Immune responses using compositions containing stress proteins |
| US7452538B2 (en) | 1997-01-28 | 2008-11-18 | Human Genome Sciences, Inc. | Death domain containing receptor 4 antibodies and methods |
| US8329179B2 (en) | 1997-01-28 | 2012-12-11 | Human Genome Sciences, Inc. | Death domain containing receptor 4 antibodies and methods |
| DE69837806T3 (de) | 1997-01-28 | 2012-01-05 | Human Genome Sciences, Inc. | "death-domain"-enthaltender rezeptor 4 (dr4), ein mitglied der tnf-rezeptor superfamilie, welcher an trail (apo-2l) bindet |
| US5830464A (en) | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
| US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
| US20050233958A1 (en) | 1997-03-17 | 2005-10-20 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| US20040136951A1 (en) | 1997-03-17 | 2004-07-15 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| US20080248046A1 (en) | 1997-03-17 | 2008-10-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| US6007821A (en) | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
| US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
| US8101349B2 (en) | 1997-12-23 | 2012-01-24 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells and their methods of use II |
| ES2355483T3 (es) * | 1998-02-20 | 2011-03-28 | University Of Miami | Complejo de proteina de choque térmico modificada-péptido antigénico. |
| JP5546084B2 (ja) | 1998-05-26 | 2014-07-09 | オプサニテクス エルエルシー | 抗原に対する免疫応答を調節する組成物および方法 |
| US6451316B1 (en) | 1998-10-05 | 2002-09-17 | University Of Conneticut Health Center | Methods for generating antigen-reactive T cells in vitro |
| US6797480B1 (en) | 1998-10-05 | 2004-09-28 | University Of Connecticut Health Center | Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents |
| US6475490B1 (en) | 1998-10-19 | 2002-11-05 | Fordham University | Compositions and methods for promoting tissue repair using heat shock proteins |
| WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
| US6317435B1 (en) | 1999-03-08 | 2001-11-13 | Qualcomm Incorporated | Method and apparatus for maximizing the use of available capacity in a communication system |
| DE60042785D1 (de) | 1999-06-09 | 2009-10-01 | Immunomedics Inc | Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern |
| US6651655B1 (en) | 2000-01-18 | 2003-11-25 | Quadrant Technologies Limited | Inhaled vaccines |
| AU2001257087A1 (en) | 2000-04-17 | 2001-10-30 | Mojave Therapeutics Inc. | Heat shock protein-based antiviral vaccines |
| US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
| NZ523408A (en) | 2000-06-26 | 2006-02-24 | Stressgen Biotechnologies Corp | Human papilloma virus treatment |
| ES2454640T3 (es) | 2000-08-03 | 2014-04-11 | Johns Hopkins University | Vacuna molecular que lleva unida un polipéptido de chaperona del retículo endoplasmático a un antígeno |
| US7132109B1 (en) | 2000-10-20 | 2006-11-07 | University Of Connecticut Health Center | Using heat shock proteins to increase immune response |
| US20070292411A1 (en) | 2000-11-08 | 2007-12-20 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
| US20060062786A1 (en) | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US20050129616A1 (en) | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| US20050214209A1 (en) | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US20050214210A1 (en) | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US7026121B1 (en) | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US20030044386A1 (en) | 2001-07-11 | 2003-03-06 | Barber Glen N. | Recombinant VSV for the treatment of tumor cells |
| WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| EP1456376A4 (en) | 2001-11-16 | 2006-09-06 | Us Gov Health & Human Serv | NEW CHIMERAL REV, TAT AND NEF ANTIGENES |
| US7955845B2 (en) | 2001-11-20 | 2011-06-07 | Dana Farber Cancer Institute, Inc. | Modified antigen-presenting cells |
| US20050214205A1 (en) | 2001-12-20 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US20050214206A1 (en) | 2001-12-20 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US20050214207A1 (en) | 2001-12-20 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind toTRAIL receptors |
| US20050214208A1 (en) | 2001-12-20 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| EP1539197A4 (en) * | 2002-02-01 | 2006-08-02 | Univ Jefferson | TREATMENT OF TUMOR CELLS FOR USE IN IMMUNOTHERAPY IN CANCER |
| EP1578773A3 (en) | 2002-02-28 | 2005-12-14 | Antigenics Inc. | Methods and products based on oligomerization of stress proteins |
| US6984389B2 (en) | 2002-04-25 | 2006-01-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| AU2003231098A1 (en) | 2002-04-25 | 2003-11-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| RU2375077C2 (ru) | 2002-05-02 | 2009-12-10 | Юниверсити Оф Коннектикут Хелт Сентер | Использование белков теплового шока для повышения эффективности терапий антителами |
| US20070298041A1 (en) | 2002-06-28 | 2007-12-27 | Tomlinson Ian M | Ligands That Enhance Endogenous Compounds |
| CA2494372C (en) | 2002-08-15 | 2013-05-28 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US7629440B2 (en) | 2002-08-20 | 2009-12-08 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
| US20040091503A1 (en) | 2002-08-20 | 2004-05-13 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
| MXPA05001953A (es) | 2002-08-20 | 2005-06-22 | Genitrix Llc | Composiciones de lecitina y metodos para modular una respuesta inmune a un antigeno. |
| CN1756568A (zh) | 2002-10-09 | 2006-04-05 | 衣阿华中央卫生系统 | 使用表达α(1,3)－半乳糖基转移酶的同种异型肿瘤细胞的抗肿瘤免疫 |
| US20060148064A1 (en) | 2002-10-25 | 2006-07-06 | Srivastava Pramod K | Apparatus and method for immunotherapy of a cancer through controlled cell lysis |
| ES2385933T3 (es) | 2003-02-20 | 2012-08-03 | University Of Connecticut Health Center | Métodos para la producción de complejos de moléculas antígenas de alfa (2) macroglobulina. |
| JP2006514088A (ja) | 2003-02-20 | 2006-04-27 | ユニバーシティー オブ コネティカット ヘルス センター | 癌および感染症の治療における熱ショックタンパク質またはα−２−マクログロブリンを含む組成物の使用方法 |
| WO2004078921A2 (en) | 2003-02-27 | 2004-09-16 | University Of Connecticut Health Center | Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes |
| ES2395126T3 (es) | 2003-02-28 | 2013-02-08 | Agenus Inc. | Uso de lectinas para promover la oligomerización de glicoproteínas y de moléculas antigénicas |
| US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| EP1633316A4 (en) | 2003-05-06 | 2008-04-02 | Human Genome Sciences Inc | ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS |
| KR100499278B1 (ko) * | 2003-07-05 | 2005-07-01 | 학교법인 포항공과대학교 | 로텍산 화합물이 공유결합된 고체 기판 및 이를 이용한바이오칩 |
| WO2005028496A2 (en) | 2003-09-12 | 2005-03-31 | Antigenics, Inc. | Vaccine for treatment and prevention of herpes simplex virus infection |
| JP4809227B2 (ja) | 2003-09-26 | 2011-11-09 | メルク セローノ ソシエテ アノニム | タンパク質の産生に使用するためのリーダー配列 |
| US20090162404A1 (en) | 2003-09-26 | 2009-06-25 | Podack Eckhard R | Tumor vaccine |
| FR2867982B1 (fr) * | 2004-03-26 | 2007-07-20 | Jean Marie Andrieu | Procede pour amplifier l'activite de vaccins therapeutiques |
| WO2005113003A2 (en) | 2004-04-16 | 2005-12-01 | Genentech, Inc. | Method for augmenting b cell depletion |
| WO2005120558A2 (en) | 2004-05-25 | 2005-12-22 | University Of Connecticut Health Center | Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| SI1810026T1 (en) | 2004-10-06 | 2018-08-31 | Mayo Foundation For Medical Education And Research | B7-H1 and PD-1 in the treatment of renal cell carcinoma |
| WO2006123256A2 (en) | 2005-02-24 | 2006-11-23 | Medical Research Council | Hivcon: an hiv immunogen and uses thereof |
| WO2007030531A2 (en) | 2005-09-06 | 2007-03-15 | Molecular Image Inc. | Reagents for testing and molecular imaging of liver cancer |
| CN101057975B (zh) | 2006-12-13 | 2012-10-10 | 中国科学院微生物研究所 | 一种抗免疫耐受性和免疫缺陷性病毒的鸡尾酒疫苗及其应用 |
| US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
| US20080206235A1 (en) | 2006-12-27 | 2008-08-28 | Johns Hopkins University | Compositions and methods for stimulating an immune response |
| KR20100063048A (ko) | 2007-07-31 | 2010-06-10 | 더 존스 홉킨스 유니버시티 | 신생물성 또는 감염성 장애의 면역예방 또는 면역치료를 위한 폴리펩티드-핵산 접합체 |
| US20100080773A1 (en) | 2008-09-26 | 2010-04-01 | Sdg, Inc. | Orally Bioavailable Lipid-Based Constructs |
| EP2257301B1 (en) | 2008-03-03 | 2014-01-22 | The University of Miami | Allogeneic cancer cell-based immunotherapy |
| CA2718884C (en) | 2008-03-20 | 2016-11-22 | University Of Miami | Heat shock protein gp96 vaccination and methods of using same |
| IL190438A0 (en) | 2008-03-25 | 2008-12-29 | K M B Y Ltd | A method of setting a drill for drilling a hole in a bone coaxial to the hole in the nail and aiming device for realizing this method |
| BRPI0909518B1 (pt) | 2008-03-26 | 2018-11-27 | Archroma Ip Gmbh | compostos branqueadores óticos, uso dos mesmos e processos para a preparação dos referidos compostos e para o branqueamento ótico de papel |
| WO2009121483A1 (en) | 2008-04-02 | 2009-10-08 | Sanofi-Aventis | Highly bridged peptides from actinomadura namibiensis |
| US10722562B2 (en) | 2008-07-23 | 2020-07-28 | Immudex Aps | Combinatorial analysis and repair |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| CN102223894A (zh) | 2008-11-21 | 2011-10-19 | 迈阿密大学 | 用于产生粘膜和系统免疫的hiv/siv疫苗 |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| WO2010081738A1 (en) | 2009-01-16 | 2010-07-22 | Agirx Limited | Vaccine compositions |
| WO2010088927A1 (en) | 2009-02-09 | 2010-08-12 | Curevac Gmbh | Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds |
| EP2413953B1 (en) | 2009-04-03 | 2017-11-08 | Agenus Inc. | Methods for preparing and using multichaperone-antigen complexes |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| US9459246B2 (en) | 2009-09-08 | 2016-10-04 | Nodality, Inc. | Induced intercellular communication |
| WO2011069528A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Lyophilization of nucleic acids in lactate-containing solutions |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US8828944B2 (en) | 2010-04-22 | 2014-09-09 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| US8865653B2 (en) | 2010-04-22 | 2014-10-21 | Institut Gustave Roussy | Method of treatment for immunogenic treatment resistant cancer |
| AU2011255463A1 (en) | 2010-05-21 | 2012-11-01 | University Of Miami | Cancer treatment |
| KR20140045341A (ko) | 2011-02-23 | 2014-04-16 | 유니버시티 오브 마이애미 | Siv/hiv로부터의 보호를 위한 조합된 세포 기반의 gp96-ig-siv/hiv, 재조합 gp120 단백질 백신접종 |
| AU2012262520A1 (en) | 2011-05-27 | 2014-01-23 | Cytocure Llc | Methods, compositions, and kits for the treatment of cancer |
| WO2014140884A2 (en) | 2013-03-15 | 2014-09-18 | Novelogics Biotechnology, Inc. | Methods and devices for removal of immunosuppressive ligands |
| CA2906356A1 (en) | 2013-03-15 | 2014-09-18 | Novelogics Biotechnology, Inc. | Antibodies to mica and micb proteins |
-
2009
- 2009-03-03 EP EP09720311.1A patent/EP2257301B1/en not_active Not-in-force
- 2009-03-03 WO PCT/US2009/001330 patent/WO2009114085A2/en not_active Ceased
- 2009-03-03 US US12/921,151 patent/US8475785B2/en not_active Expired - Fee Related
- 2009-03-03 ES ES09720311.1T patent/ES2460899T3/es active Active
- 2009-03-03 EP EP14152006.4A patent/EP2752193B1/en active Active
- 2009-03-03 JP JP2010549646A patent/JP2011513399A/ja active Pending
- 2009-03-03 CN CN200980115985XA patent/CN102014937A/zh active Pending
- 2009-03-03 CA CA2717854A patent/CA2717854C/en active Active
- 2009-03-03 DK DK09720311.1T patent/DK2257301T3/da active
- 2009-03-03 AU AU2009223838A patent/AU2009223838B2/en not_active Ceased
- 2009-03-03 KR KR1020107022069A patent/KR20110009095A/ko not_active Ceased
-
2010
- 2010-09-02 IL IL207958A patent/IL207958A/en active IP Right Grant
-
2013
- 2013-06-28 US US13/930,818 patent/US9238064B2/en active Active
-
2014
- 2014-07-04 JP JP2014138932A patent/JP2014208690A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009223838A1 (en) | 2009-09-17 |
| CA2717854C (en) | 2019-02-19 |
| AU2009223838B2 (en) | 2012-07-26 |
| EP2257301A2 (en) | 2010-12-08 |
| US8475785B2 (en) | 2013-07-02 |
| US9238064B2 (en) | 2016-01-19 |
| US20130302376A1 (en) | 2013-11-14 |
| CN102014937A (zh) | 2011-04-13 |
| KR20110009095A (ko) | 2011-01-27 |
| EP2257301B1 (en) | 2014-01-22 |
| EP2752193B1 (en) | 2017-01-11 |
| US20110250229A1 (en) | 2011-10-13 |
| JP2011513399A (ja) | 2011-04-28 |
| DK2257301T3 (da) | 2014-04-28 |
| IL207958A (en) | 2015-09-24 |
| EP2257301A4 (en) | 2013-01-16 |
| EP2752193A1 (en) | 2014-07-09 |
| WO2009114085A3 (en) | 2009-12-03 |
| CA2717854A1 (en) | 2009-09-17 |
| JP2014208690A (ja) | 2014-11-06 |
| IL207958A0 (en) | 2010-12-30 |
| WO2009114085A2 (en) | 2009-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2460899T3 (es) | Inmunoterapia basada en células cancerosas alógenas | |
| CN110475571B (zh) | 细胞免疫疗法前细胞毒性预调理的替代 | |
| ES2328025T3 (es) | Mejoramiento de las respuestas inmunitarias por anticuerpos agonistas 4-1 bb. | |
| JP6993240B2 (ja) | 結腸直腸癌を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 | |
| JP5239041B2 (ja) | 癌の治療剤 | |
| ES2686424T5 (es) | Inmunoterapia con células alogénicas redireccionadas | |
| CN111148533A (zh) | 用于嵌合抗原受体t细胞疗法的组合物及其用途 | |
| Strbo et al. | Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases | |
| Su et al. | Anti-tumor efficacy of a hepatocellular carcinoma vaccine based on dendritic cells combined with tumor-derived autophagosomes in murine models | |
| ES2769326T3 (es) | Métodos y composiciones para la inmunoterapia contra el cáncer usando células tumorales que expresan la proteína de fusión de flagelina y antígeno asociado al tumor | |
| JP2021500882A (ja) | スペーサーを含むポリペプチド組成物 | |
| AU2015233542B2 (en) | A medicament for use in a method of inducing or extending a cellular cytotoxic immune response | |
| Akutsu et al. | Combination of direct intratumoral administration of dendritic cells and irradiation induces strong systemic antitumor effect mediated by GRP94/gp96 against squamous cell carcinoma in mice | |
| RU2709015C2 (ru) | Лекарственное средство | |
| Zhang et al. | Neoantigen sequestrated autophagosomes as therapeutic cancer vaccines | |
| JP6077641B2 (ja) | 新規ｃｔｌエピトープ５連結ペプチド | |
| US20230355678A1 (en) | Methods for improving t cell efficacy | |
| CN109069599A (zh) | 针对癌症的基于ptp的疫苗 | |
| Jæhger | Preclinical Evaluation of Novel Drug Delivery Platforms for the Improvement of Adoptive T cell Therapy | |
| HK40026581A (en) | Compositions for chimeric antigen receptor t cell therapy and uses thereof | |
| Zhou et al. | Blocking Blood Supply to Breast Carcinoma With a DNA Vaccine Encoding VEGF Receptor-2 | |
| Veiga et al. | Lymphocytes transfectes pour therapie antitumorale | |
| Bannister et al. | Role of CTLA4 in tumor immunity |